These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38267451)

  • 21. Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A cross-sectional analysis of the National Health and Nutrition Examination Survey.
    Gor D; Gerber BS; Walton SM; Lee TA; Nutescu EA; Touchette DR
    J Diabetes; 2020 May; 12(5):385-395. PubMed ID: 31652390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin Treatment in Patients With Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4.
    Lalau JD; Kajbaf F; Bennis Y; Hurtel-Lemaire AS; Belpaire F; De Broe ME
    Diabetes Care; 2018 Mar; 41(3):547-553. PubMed ID: 29305402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of Metformin Use in Diabetic Kidney Disease.
    Kawanami D; Takashi Y; Tanabe M
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin Use and Risk of All-Cause Mortality and Cardiovascular Events in Patients With Chronic Kidney Disease-A Systematic Review and Meta-Analysis.
    Hu Y; Lei M; Ke G; Huang X; Peng X; Zhong L; Fu P
    Front Endocrinol (Lausanne); 2020; 11():559446. PubMed ID: 33117278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology of lactic acidosis in type 2 diabetes patients with metformin in Japan.
    Chang CH; Sakaguchi M; Dolin P
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1196-1203. PubMed ID: 27221971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metformin reduces the increased risk of oral squamous cell carcinoma recurrence in patients with type 2 diabetes mellitus: A cohort study with propensity score analyses.
    Hu X; Xiong H; Chen W; Huang L; Mao T; Yang L; Wang C; Huang D; Wang Z; Yu J; Shu Y; Xia K; Su T
    Surg Oncol; 2020 Dec; 35():453-459. PubMed ID: 33065527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study.
    Whitlock RH; Hougen I; Komenda P; Rigatto C; Clemens KK; Tangri N
    Mayo Clin Proc; 2020 Jan; 95(1):90-100. PubMed ID: 31902433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin use in patients with type 2 diabetes mellitus and chronic kidney disease: An evidence-based review.
    Tan FCJH; Ang SB; Bee YM
    Ann Acad Med Singap; 2021 Feb; 50(2):159-170. PubMed ID: 33733259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
    Chan CW; Yu CL; Lin JC; Hsieh YC; Lin CC; Hung CY; Li CH; Liao YC; Lo CP; Huang JL; Lin CH; Wu TJ
    Cardiovasc Diabetol; 2018 Jan; 17(1):20. PubMed ID: 29368615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study.
    Hung SC; Chang YK; Liu JS; Kuo KL; Chen YH; Hsu CC; Tarng DC
    Lancet Diabetes Endocrinol; 2015 Aug; 3(8):605-14. PubMed ID: 26094107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism and application of metformin in kidney diseases: An update.
    Song A; Zhang C; Meng X
    Biomed Pharmacother; 2021 Jun; 138():111454. PubMed ID: 33714781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression of established non-diabetic chronic kidney disease is halted by metformin treatment in rats.
    Corremans R; Neven E; Maudsley S; Leysen H; De Broe ME; D'Haese PC; Vervaet BA; Verhulst A
    Kidney Int; 2022 May; 101(5):929-944. PubMed ID: 35271933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lactate levels and risk of lactic acidosis with metformin in diabetic kidney disease patients.
    Bipi PK; George J; Gomathy S; Gracious N; Kumar S; Mohandas MK
    Saudi J Kidney Dis Transpl; 2017; 28(6):1356-1361. PubMed ID: 29265047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of clinical predictors of diabetic nephropathy and non-diabetic renal disease in Chinese patients with type 2 diabetes, with reference to disease course and outcome.
    Wang J; Han Q; Zhao L; Zhang J; Wang Y; Wu Y; Wang T; Zhang R; Grung P; Xu H; Liu F
    Acta Diabetol; 2019 Aug; 56(8):939-946. PubMed ID: 30927104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal pathological implications in type 2 diabetes mellitus patients with renal involvement.
    Li L; Zhang X; Li Z; Zhang R; Guo R; Yin Q; Yang L; Yue R; Su B; Huang S; Xu H; He C; Liu F
    J Diabetes Complications; 2017 Jan; 31(1):114-121. PubMed ID: 27838100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study.
    Richy FF; Sabidó-Espin M; Guedes S; Corvino FA; Gottwald-Hostalek U
    Diabetes Care; 2014 Aug; 37(8):2291-5. PubMed ID: 24879835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metformin mediates MicroRNA-21 regulated circulating matrix metalloproteinase-9 in diabetic nephropathy: an in-silico and clinical study.
    Khokhar M; Roy D; Bajpai NK; Bohra GK; Yadav D; Sharma P; Purohit P
    Arch Physiol Biochem; 2023 Dec; 129(6):1200-1210. PubMed ID: 34087084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
    Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
    JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycemic Control and Adverse Clinical Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus: Results from KNOW-CKD.
    Heo GY; Koh HB; Kim HW; Park JT; Yoo TH; Kang SW; Kim J; Kim SW; Kim YH; Sung SA; Oh KH; Han SH
    Diabetes Metab J; 2023 Jul; 47(4):535-546. PubMed ID: 37096377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.